









Markets
/
Stocks
/
nasdaq-dawn
/

Day One Biopharmaceuticals Inc

DAWN

7.310USD

0.0000.00%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

748.78MMarket Cap

LossP/E TTM



Day One Biopharmaceuticals Inc

7.310

0.0000.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Day One Biopharmaceuticals Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Day One Biopharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

55 / 407

Overall Ranking

153 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

23.250

Target Price

+212.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Day One Biopharmaceuticals Inc Highlights

StrengthsRisks

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Fairly Valued

The company’s latest PE is -8.13, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.03M shares, decreasing 27.18% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 40.23K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.76.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 33.91M, representing a year-over-year increase of 313.92%, while its net profit experienced a year-over-year increase of 588.04%.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

6.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.05

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.49

Key Metrics

Free cash flow

No Data

Day One Biopharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.27, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -8.13, which is -48.10% below the recent high of -4.22 and -108.30% above the recent low of -16.93.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Day One Biopharmaceuticals Inc is 25.00, with a high of 34.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

23.250

Target Price

+212.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Day One Biopharmaceuticals Inc

DAWN

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.34, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 7.97 and the support level at 6.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.29

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Neutral

RSI(14)

50.532

Neutral

STOCH(KDJ)(9,3,3)

39.505

Buy

ATR(14)

0.416

Low Volatility

CCI(14)

3.215

Neutral

Williams %R

65.833

Sell

TRIX(12,20)

0.065

Sell

StochRSI(14)

67.651

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.232

Buy

MA10

7.328

Sell

MA20

7.352

Sell

MA50

7.269

Buy

MA100

6.950

Buy

MA200

7.844

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 84.96%, representing a quarter-over-quarter decrease of 23.36%. The largest institutional shareholder is The Vanguard, holding a total of 6.16M shares, representing 6.02% of shares outstanding, with 3.98% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Access Industries, Inc.

12.93M

Fidelity Management & Research Company LLC

9.20M

-19.19%

BlackRock Institutional Trust Company, N.A.

6.80M

+31.20%

Atlas Venture

6.43M

The Vanguard Group, Inc.

Star Investors

6.16M

+3.93%

Franklin Advisers, Inc.

4.05M

+1.86%

Deerfield Management Company, L.P.

3.72M

+25.75%

Pictet Asset Management Ltd.

3.72M

+2.40%

Alyeska Investment Group, L.P.

3.01M

-25.80%

Vestal Point Capital, LP

3.00M

+15.47%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 5.34, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -1.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.